Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406940 | 0.98 | SLC9A1 (0.44) | SLC9A1GRM2KMT2AMEN1HTT | |
| SCHEMBL4416327 | 0.94 | GRM2 (0.44) | SLC9A1GRM2KMT2AMEN1HTT | |
| SCHEMBL4408930 | 0.85 | — | — | |
| SCHEMBL2088514 | 0.78 | P2RX7 (0.46) | SLC9A1KMT2AMEN1HTTLMNA | |
| SCHEMBL544848 | 0.78 | CYP1A2 (0.55) | SLC9A1KMT2AMEN1HTTLMNA | |
| SCHEMBL4404458 | 0.76 | — | — | |
| SCHEMBL1027818 | 0.76 | CYP1A2 (0.53) | SLC9A1KMT2AMEN1HTTCYP1A2 | |
| SCHEMBL9872492 | 0.76 | CYP1A2 (0.53) | SLC9A1KMT2AMEN1HTTCYP1A2 | |
| SCHEMBL2051081 | 0.76 | SLC9A1 (0.42) | SLC9A1KMT2AMEN1HTTLMNA | |
| SCHEMBL4405197 | 0.76 | SLC9A1 (0.42) | SLC9A1KMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039714-A1 | Probes, Systems, and Methods for Drug Discovery | VTVX HOLDINGS I LLC | 2011-02-17 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| CN-1533400-A | Probes, system and methods for drug discovery | ����˹̩����ҩ��˾ | 2004-09-29 | — | — | CN | disclosed |
| EP-1383799-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TransTech Pharma Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003084997-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TRANSTECH PHARMA, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | TRANSTECH PHARMA, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | ABCG2, EZR, PAICS | SLC9A1 4778/4885GRM2 4544/4885KMT2A 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.